Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

Mergers & acquisitions

February 8, 2013: 9:43 AM ET

Alere Inc. (NYSE: ALR) has acquired Epocal Inc., an Ottawa–based provider of technologies that support blood gas and electrolyte testing at the point of care. The deal is valued at upwards of $241.5 million, including a $166 million up-front cash payment. Epocal had raised over $30 million in VC funding from firms like Highland Capital Management, Genesys Capital Partners, MM Venture Partners, New Generation Biotech and Covington Capital. www.alere.com

Salesforce.com (NYSE: CRM) has acquired EntropySoft, a Paris-based content connection software startup. No financial terms were disclosed. EntropySoft had been seeded by Alven Capital. www.salesforce.com

Curtiss-Wright Corp. (NYSE: CW) has acquired Exlar Corp., a Chanhassen, Minn.–based maker of actuators used in motion control solutions for the industrial and military markets. The deal was valued at $85 million in cash, with Greene Holcomb & Fisher managing the process. www.exlar.com

Decade Sunshine Ltd. has agreed to acquire 3SBio Inc. (NASDAQ: SSRX), a Chinese biotech company, for around $350 million, or $15.40 per share. The company previously had received a $15 per share offer from CITIC Private Equity and 3SBio chairman and CEO Jing Lou. www.3sbio.com

FolioDynamix Corp
., a New York-based provider of fee-based managed account solutions for the wealth management industry, has acquired Access Partners, a registered investment advisor focused on trust investment management and operations. No pricing terms of the all-cash transaction were disclosed. FolioDynamics has raised over $24 million in VC funding from ABS Capital Partners, Edison Ventures, Cambrian and Velocity Financial Group. www.foliodynamix.com

Tranzyme (Nasdaq: TZYM) said that it has hired Stifel to explore strategic alternatives, including a possible sale of the company. The Durham, N.C.-based company went public less than two years ago, but recently stopped late-stage clinical trials on a new treatment for stomach paralysis due to lack of efficacy. The company's market cap is around $15 million. www.tranzyme.com

Sign up for my daily email newsletter on deals and deal-makers: GetTermSheet.com

Posted in:
Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.